Is Weed Addiction Real? Cannabis Use Disorder Explained

Cannabis Use Disorder is a real, DSM-5-recognised diagnosis, not an outdated scare story — long-term use is linked to addiction in roughly 9% of users overall, rising to 25-50% among daily users. Today’s cannabis is also far stronger than a generation ago, which sharply raises the risk of dependence and psychosis, especially in young and daily users. This article explains what the evidence shows, why cannabis addiction is so often minimised, and what an evidence-based treatment pathway looks like.

You’ve told yourself it’s not like other drugs. No needles, no comedowns, no crime. Everyone you know does it. But lately you’re smoking before work, hiding how much you actually use, and feeling anxious without it. Somewhere between “it’s just weed” and where you are now, a question has started forming that you can’t quite shake: is weed addiction actually real, or is that just something people say?

If you’re a partner, parent, or friend reading this instead, you’ve probably watched someone you love get quieter, more withdrawn, more defensive about something that “everyone does.” You’re not overreacting, and you’re not imagining it.

Cannabis occupies a strange cultural position. It’s decriminalised or legal in parts of the world, prescribed medically in the UK for specific conditions, and normalised across professional life in a way that alcohol was a generation ago. Yet none of that changes the underlying pharmacology — cannabis is still capable of producing a diagnosable, DSM-5-recognised use disorder. Today’s cannabis is also not the cannabis your parents or partner might be picturing; potency has changed dramatically, and so has the risk profile that comes with it.

This piece sets out what the evidence actually shows about weed addiction, why it’s harder to recognise than dependence on other substances, and what a real treatment pathway looks like.

Is Cannabis Actually Addictive?

The short answer is yes — and it has a clinical name. Cannabis Use Disorder (CUD) is formally recognised in the DSM-5-TR, the diagnostic manual used by clinicians worldwide, with a defined set of criteria summarised via NIH/NCBI’s StatPearls reference on Cannabis Use Disorder. Those criteria include using more cannabis than intended, unsuccessful attempts to cut down or stop, persistent cravings, continued use despite clear harm to health, relationships, or work, and — critically — the development of tolerance and withdrawal. This is not an informal label; it’s the same diagnostic framework used to identify alcohol or opioid use disorder, applied to cannabis.

The scale of the risk is well documented. Writing in the New England Journal of Medicine in 2014, Volkow and colleagues found that long-term cannabis use is associated with addiction in around 9% of people who use it overall — a figure that rises to roughly 17% among those who begin using in adolescence, and climbs further still, to somewhere between 25% and 50%, among people who use daily. In other words, the “just weed” framing collapses fastest for exactly the people most likely to be reading this: daily users, and people who started young.

Withdrawal is the other half of the picture, and it’s just as clinically real. Cannabis withdrawal syndrome was formally added to the DSM-5 in 2013, with a recognised symptom set: irritability, anxiety, disrupted sleep, decreased appetite, and physical symptoms including headaches, sweating, tremor, and abdominal pain — typically emerging within about a week of stopping heavy, prolonged use. None of that is a moral failing; tolerance and withdrawal are physiological facts, not character flaws.

That’s worth naming directly, because it’s the myth doing the most damage: the absence of needles or overdose risk does not mean the absence of dependence risk. In the UK specifically, cannabis remains the most commonly used controlled drug, and that familiarity tends to breed denial — both in the person using and in the people around them who’ve come to see it as background noise rather than a substance with its own risk profile.

How Many People Are We Actually Talking About?

This isn’t a fringe concern. According to the Office for National Statistics’ “Drug misuse in England and Wales” report for the year ending March 2024, 6.8% of people aged 16 to 59 in England and Wales reported using cannabis in the previous year — roughly 2.3 million people — a slight decline from 7.6% (around 2.5 million) the year before.

Younger adults carry a disproportionate share of that risk. The same ONS data puts cannabis use among 16-to-24-year-olds at somewhere between 13.8% and 15.4%, more than double the all-ages rate. Frequency matters as much as headline prevalence here: over a third of past-year users reported using cannabis more than once a month, and 8.3% used it every single day — a pattern squarely inside the 25–50% daily-use addiction range identified by Volkow and colleagues above.

The treatment system reflects this. Data from the Office for Health Improvement and Disparities shows cannabis is now the single most common substance cited by young people entering drug and alcohol treatment in England, referenced by the large majority of young people who enter treatment at all. Among adults, OHID’s substance misuse treatment statistics point to a clear and rising share of new treatment entrants citing cannabis, even as opiates and alcohol remain the largest overall adult treatment groups. This is not a fringe issue — it is the most common reason young people in the UK enter drug treatment, full stop.

Why Is Today’s Cannabis Different From a Generation Ago?

Part of why the “just weed” instinct persists is generational — and it’s based on a product that, in many cases, no longer exists. Home Office forensic analysis of seized cannabis found average THC potency in “skunk”-type sinsemilla samples of around 16.2%, with a range up to 46%. Broader trend data cited in the peer-reviewed potency-tracking literature shows average THC content climbing from roughly 5% in the early 2000s to over 20% in flower today, and upwards of 60% in concentrated extracts. The cannabis someone “smoked a bit” of at university, twenty or thirty years ago, was a materially weaker drug than what’s now commonly available.

That potency increase isn’t just a stronger high — it’s a materially different risk calculation, particularly around psychosis. The landmark European case-control study led by Di Forti and colleagues, published in The Lancet Psychiatry in 2019 as part of the EU-GEI project, found that daily cannabis users had roughly 3.2 times the odds of experiencing a first episode of psychosis compared with non-users. Among users of high-potency cannabis specifically — defined as above 10% THC — those odds rose to roughly 4.8 times.

That dose-response relationship has been confirmed independently. A 2016 meta-analysis by Marconi, Di Forti, and colleagues in Schizophrenia Bulletin, covering more than 66,000 people, found the heaviest cannabis users had nearly four times the odds (an odds ratio of 3.90) of psychosis-related outcomes compared with non-users, with risk climbing in step with level of use. This built on earlier foundational work: a 2007 systematic review by Moore and colleagues in The Lancet had already linked cannabis use overall to a roughly 40% increased risk of psychotic outcomes, rising to between 50% and 200% in the heaviest users.

For families, this is the single most useful fact in the whole piece: the person you knew who “smoked a bit at university” was using a fundamentally weaker drug than what’s typically available now. Arguing from that outdated reference point is arguing from bad data.

Can Cannabis Cause or Worsen Behavioural Health Problems?

The Royal College of Psychiatrists is explicit on this point: the younger someone starts using cannabis, and the more regularly and potently they use it, the greater their risk of psychosis. Daily use is linked with depression, anxiety, and reduced motivation, and in vulnerable individuals can raise psychosis risk severalfold — with adolescents carrying particular risk given ongoing brain development. In a statement issued in May 2025, responding directly to the London Drugs Commission, the Royal College of Psychiatrists went further still: even small amounts of cannabis used daily can cause significant harm, pushing back explicitly on the assumption that risk is confined to “heavy” users alone.

This is exactly where Holina’s dual treatment model becomes relevant rather than theoretical. Cannabis use disorder frequently doesn’t arrive alone — it sits alongside anxiety, depression, or unresolved trauma, sometimes as a form of self-medication and sometimes as a consequence of the use itself. It’s worth being precise here: this is a single, interconnected behavioural health picture, not two separate and unrelated problems bolted together. The relationship runs in both directions. Cannabis can precipitate or worsen behavioural health difficulties in people who are vulnerable to them, and, just as often, people already living with anxiety, depression, or trauma histories use cannabis to self-soothe — which can entrench both problems at once rather than resolving either.

None of this is intended as scare language or a moral verdict. It’s a clinical risk profile, described plainly, because understating it doesn’t help anyone make a genuinely informed decision.

Why Is It So Hard to Quit If Cannabis “Isn’t That Addictive”?

If you’ve tried to stop and found it harder than expected, that’s not a sign you’re weak-willed — it’s a predictable feature of dependence. Cravings, withdrawal-driven relapse, and psychological reliance on cannabis for sleep, anxiety relief, or social ease are all recognised barriers to quitting, and they operate independently of whether the substance carries an overdose risk.

Part of the difficulty is structural, not personal: there is currently no FDA- or MHRA-approved medication for treating cannabis use disorder directly. The Cochrane Library’s most recent review of pharmacotherapies for cannabis use disorder — an update by Spiga and colleagues in 2025, building on earlier work by Nielsen and colleagues in 2019 — confirms this is a genuine gap in the treatment landscape, not a reason to skip treatment altogether.

What the evidence does support is structured psychosocial treatment. Cochrane and NIH systematic reviews consistently point to intensive, multi-session combinations of Cognitive Behavioural Therapy (CBT) and Motivational Enhancement Therapy (MET) — sometimes paired with abstinence-based incentives — as reliably reducing frequency of use and dependence severity, at least short-to-medium term. The honest caveat: psychosocial treatment alone doesn’t reliably resolve co-occurring behavioural health symptoms or other substance use, which is precisely why integrated, whole-person treatment matters more than a single-modality quick fix. In the UK, this isn’t just clinical opinion — NICE Guideline CG51 recommends psychosocial interventions as first-line treatment for cannabis dependence in over-16s, delivered as part of a coordinated care pathway.

How Holina Rehab Treats Cannabis Use Disorder

Cannabis use disorder rarely presents in isolation. Most clients arrive at Holina with a dual treatment picture — cannabis dependence intersecting with anxiety, depression, trauma, or burnout — and our Dual Treatment programme is built around treating both simultaneously, rather than addressing one and hoping the other resolves on its own.

Our approach draws on NARM and somatic therapy, a trauma-informed methodology addressing the nervous-system and attachment patterns often underlying long-term, high-frequency cannabis use — particularly where cannabis has functioned as chronic self-regulation against anxiety or unresolved trauma. Withdrawal itself is managed in a medically supervised environment, with structured support from our clinical team for the irritability, sleep disruption, appetite change, and cravings that characterise cannabis withdrawal syndrome, delivered in a private, monitored clinical setting rather than left to the “white-knuckle it alone” approach that drives so much early relapse.

We also use Hyperbaric Oxygen Therapy (HBOT) as an adjunct modality supporting neurological and cognitive recovery during early abstinence, and draw on mindfulness and Buddhist-influenced recovery practices, leveraging our Thailand clinical setting for structured meditation and present-moment work that targets the anxiety-and-craving cycle cannabis use disorder tends to produce.

Because cannabis use disorder is so often minimised by the people closest to the person affected — “it’s not heroin” being the recurring line — family therapy is built into treatment early, directly addressing enabling patterns and rebuilding trust and communication through our dedicated support for families. And because relapse risk here is driven far more by long-term psychological reliance — on cannabis for sleep, social ease, or anxiety relief — than by acute physical withdrawal alone, our Thrucare programme extends structured aftercare across two years. Short residential stays without extended follow-up consistently underserve exactly this pattern of relapse risk.

What we offer is an integrated, private, internationally staffed treatment model — not a promise, and not a fabricated success percentage. It’s a considered clinical approach built around how cannabis use disorder actually behaves in practice.

What Families Can Do Now

Arguing head-on against the “it’s just weed” framing rarely lands — it tends to put the other person on the defensive before the conversation has properly started. It’s usually more effective to name specific behaviour changes you’ve observed — withdrawal from things they used to enjoy, missed commitments, shifts in mood, growing secrecy — rather than debating the substance in the abstract.

Ultimatums delivered in anger tend to entrench denial rather than break through it. A calm, specific, evidence-led conversation gets further than a confrontation. It’s worth going in informed: understanding current cannabis potency, as covered above, matters, because many parents and partners are unknowingly arguing from a decades-outdated picture of the drug.

Perhaps most importantly, don’t wait for a “rock bottom” that may never arrive. Because there’s no overdose event or dramatic crisis point forcing the issue with cannabis, families often wait years longer than they would with other substances — and early intervention still works, even before things have visibly fallen apart. Where possible, reach out to our support for families team for a confidential family consultation before staging an intervention alone; professional guidance measurably improves the outcome of that first conversation. If you’re ready to talk it through, you can speak with our admissions team at any time. Throughout, keep the door open. Cannabis use disorder is a behavioural health condition, not a moral failing, and the language used around it plays a real role in keeping someone receptive to help.

Frequently asked questions

Is weed addiction real, or is that outdated thinking?

Yes. Cannabis Use Disorder is formally recognised in the DSM-5-TR, with diagnostic criteria including tolerance, withdrawal, and continued use despite harm. Volkow and colleagues (New England Journal of Medicine, 2014) found roughly 9% of people who use cannabis develop dependence, rising sharply with early-onset and daily use.

What’s the difference between using cannabis and having Cannabis Use Disorder?

DSM-5 criteria distinguish use from disorder based on loss of control rather than frequency alone: using more than intended, failed attempts to cut down, persistent cravings, and continued use despite clear harm to health, relationships, or responsibilities.

Can you get withdrawal symptoms from cannabis?

Yes. Cannabis withdrawal syndrome is a recognised DSM-5 diagnosis, with symptoms including irritability, anxiety, sleep disturbance, appetite loss, and physical symptoms such as headaches and tremors — typically emerging within about a week of stopping heavy, regular use.

Does high-potency cannabis really carry more risk?

Substantially more. A major European study by Di Forti and colleagues, published in The Lancet Psychiatry (2019), found that daily users of high-potency cannabis (above 10% THC) had nearly five times the odds of a first psychotic episode compared with non-users.

Can cannabis cause behavioural health problems, or does it just reveal them?

Both dynamics exist. Cannabis can precipitate psychosis and worsen anxiety or depression in vulnerable people, while others use cannabis to self-medicate existing conditions — entrenching both problems at once. This is exactly why Holina treats it as a dual treatment picture, rather than one isolated issue.

Is medication available to treat cannabis dependence?

Not currently. No medication is approved specifically for cannabis use disorder or its withdrawal, according to the Cochrane Library’s 2025 review. The strongest evidence supports structured psychosocial treatment — particularly combined CBT and motivational therapy.

My relative says “it’s legal/medical where I live” — does that mean it’s not addictive?

Legal status doesn’t change the underlying pharmacology. Cannabis Use Disorder is diagnosed the same way regardless of legal status, and today’s higher-potency products carry meaningfully more dependence and psychosis risk than the cannabis available a generation ago.

How long does cannabis use disorder treatment take?

There’s no universal timeline. Because relapse risk is driven by long-term psychological patterns — sleep, anxiety relief, social habit — rather than acute physical withdrawal alone, extended aftercare, not just a short residential stay, is critical to durable recovery.

Is it “just weed” if there’s no overdose risk?

Overdose risk isn’t what defines addiction. Dependence, withdrawal, and impairment to daily life are diagnostic criteria independent of overdose potential, and cannabis use disorder can still derail careers, relationships, and behavioural health without any overdose event ever occurring.

What should I do if I’m not sure it’s “bad enough” to seek help?

Contact a treatment team for a confidential assessment rather than trying to decide alone. Cannabis use disorder is frequently under-recognised precisely because there’s no dramatic crisis moment forcing the issue — and waiting for one often means waiting years too long.

Clinically reviewed by Dr. Natalie Lindemann — Clinical Director, Holina Global · Last reviewed 18 August 2026.